Bioenvision to Host Third Quarter 2006 Financial Results Conference Call
May 09 2006 - 3:01PM
Business Wire
Bioenvision (NASDAQ: BIVN) today announced that the Company will
host a conference call with the financial community to discuss the
third quarter 2006 financial results on Monday, May 15, 2006 at
10:00 a.m. EST. To participate in the live call by telephone,
please dial 877-715-5320 from the U.S. and Canada or 973-582-2853
from outside the U.S. A telephone replay of the call will be
available beginning at 12:00 p.m. EST May 15th until 11:59 p.m. EST
May 29th by dialing 877-519-4471 or 973-341-3080 and entering
reservation number 7373873. Those interested in listening to the
conference call live via the Internet may do so by visiting
www.vcall.com where a link to Bioenvision's conference call can be
found. Please go to the web site 15 minutes prior to its start to
register, download, and install the necessary audio software. A
replay will be available for 14 days. About Bioenvision
Bioenvision's primary focus is the acquisition, development and
distribution of compounds and technologies for the treatment of
cancer. Bioenvision has a broad pipeline of products for the
treatment of cancer, including: Clofarabine (in co-development with
Genzyme Corporation), Modrenal(R) (for which Bioenvision has
obtained regulatory approval for marketing in the United Kingdom
for the treatment of post-menopausal breast cancer following
relapse to initial hormone therapy), and other products in clinical
trials. Bioenvision is also developing anti-infective technologies,
including Suvus for hepatitis-C and the OLIGON technology; an
advanced biomaterial that has been incorporated into various FDA
approved medical devices. For more information on Bioenvision
please visit our web site at www.bioenvision.com. Certain
statements contained herein are "forward-looking" statements (as
such term is defined in the Private Securities Litigation Reform
Act of 1995). Because these statements include risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements.
Specifically, factors that could cause actual results to differ
materially from those expressed or implied by such forward-looking
statements include, but are not limited to: risks associated with
preclinical and clinical developments in the biopharmaceutical
industry in general and in Bioenvision's compounds under
development in particular; the potential failure of Bioenvision's
compounds under development to prove safe and effective for
treatment of disease; uncertainties inherent in the early stage of
Bioenvision's compounds under development; failure to successfully
implement or complete clinical trials; failure to receive marketing
clearance from regulatory agencies for our compounds under
development; acquisitions, divestitures, mergers, licenses or
strategic initiatives that change Bioenvision's business, structure
or projections; the development of competing products;
uncertainties related to Bioenvision's dependence on third parties
and partners; and those risks described in Bioenvision's filings
with the SEC. Bioenvision disclaims any obligation to update these
forward-looking statements.
Bioenvision (NASDAQ:BIVN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bioenvision (NASDAQ:BIVN)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Bioenvision (MM) (NASDAQ): 0 recent articles
More Bioenvision News Articles